Home  /   Products  /   Painkillers  /   Meloxicam (Genitron) injection 10 mg/ml 1.5 ml – [5 ampoules]

Meloxicam (Genitron) injection 10 mg/ml 1.5 ml – [5 ampoules]



SKU: 61343 Category:


Genitron Pharmacodynamics
Meloxicam is a non-steroidal anti-inflammatory drug with anti-inflammatory, antipyretic, analgesic effects. It belongs to the class of oxycams, a derivative of enolic acid. Mechanism of action – inhibition of prostaglandin (Pg) synthesis as a result of selective inhibition of cyclooxygenase 2 (COX-2) enzymatic activity. When prescribed in high doses, prolonged use and individual characteristics of the body COX-2 selectivity is reduced. It suppresses Pg synthesis in the area of inflammation to a greater extent than in the gastrointestinal mucosa or kidneys, which is due to the relatively selective inhibition of COX-2, whereas inhibition of the ever-present COX-1 isoenzyme may cause gastrointestinal (GI) and renal side effects.

Short-term symptomatic therapy of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and other joint diseases accompanied by pain syndrome.
The drug is intended to reduce pain and inflammation at the time of use, does not affect the progression of the disease.

– Hypersensitivity to the active substance or excipients (including other NSAIDs);
– complete or incomplete combination of bronchial asthma, recurrent polyposis of nasal mucosa and paranasal sinuses, and intolerance to acetylsalicylic acid and other NSAIDs (including history);
– erosive-ulcerative changes of the mucous membrane of the stomach and duodenum, active gastrointestinal bleeding;
– ulcerative colitis, acute Crohn’s disease;
– Severe hepatic insufficiency or active liver disease;
– severe renal failure (unless hemodialysis is performed, creatinine clearance (CK) less than 30 ml/min, and with confirmed hyperkalemia), advanced renal disease;
– acute gastrointestinal bleeding, recent cerebrovascular bleeding, or a confirmed diagnosis of clotting disorders;
– Severe uncontrolled heart failure;
– Contraindicated during the period following aortocoronary bypass surgery;
– pregnancy;
– Breast-feeding period;
– Children under 18 years of age.

Dosage and administration method

  • Intramuscular administration of the drug is shown only during the first 2-3 days. Further treatment is continued with oral forms (tablets).
  • The recommended dose is 7.5 mg or 15 mg 1 time per day, depending on the intensity of pain and severity of the inflammatory process.
  • The maximum recommended daily dose is 15 mg.
  • The drug is administered deeply intramuscularly. Intravenous administration of the drug is prohibited!
  • Given the possible incompatibility, meloxicam should not be mixed in one syringe with other drugs.
  • For patients with increased risk of adverse reactions and with significant renal failure, which are on hemodialysis, the daily dose should not exceed 7.5 mg.
  • No dose adjustment is required for patients with mild to moderate renal impairment (CKD over 30 ml/min).
  • The drug should not be used simultaneously with other NSAIDs.
  • The total daily dose of meloxicam used in the form of tablets, suppositories, oral and injections should not exceed 15 mg.